Dr. Claudia Lindemann

Dr. Claudia Lindemann is currently the Director Non-clinical Safety at BioNTech SE, where Dr. Claudia is responsible for the development of novel pharmaceuticals in various therapeutic areas. Prior to their current role, Dr. Claudia was a PhD Student at the University of Oxford, where Dr. Claudia identified antigens for a novel Staphylococcus aureus vaccine. Dr. Claudia also has experience as a Graduate Research Intern at GSK Vaccines and as a Praktikant at Merck Group. Dr. Lindemann holds a DPhil in Clinical Medicine specializing in Vaccine Research and Development from the University of Oxford and has a Master of Science in Pharmaceutical Science as well as a Bachelor of Science in Chemical Biology.